Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy

  • Zou, Zhi-Qiang (Department of Thoracic Surgery, Jinan Military General Hospital) ;
  • Du, Yi-Ying (Department of Thoracic Surgery, Jinan Military General Hospital) ;
  • Sui, Gang (Department of Thoracic Surgery, Jinan Military General Hospital) ;
  • Xu, Shi-Ning (Department of Thoracic Surgery, Jinan Military General Hospital)
  • Published : 2015.04.29


Background: To explore the expression of TS, RRM, ERCC1, TUBB3 and STMN1 genes in the tissues of patients with non-small cell lung cancer (NSCLC) and its significance in guiding the postoperative adjuvant chemotherapy. Materials and Methods: Real time polymerase chain reaction (PCR) was applied to detect the expression of TS, RRM, ERCC1, TUBB3 and STMN1 genes in the tissues of NSCLC patients so as to analyze the relationship between the expression of each gene and the clinical characteristics and to guide the postoperative individualized chemotherapy according to the detection results of NSCLC patients. Results: Expression of TS gene was evidently higher in patients with adenocarcinoma than those with non-adenocarcinoma (P=0.013) and so was the expression of ERCC1 (P=0.003). The expression of TUBB3 gene was obviously higher in NSCLC patients in phases I/II and IV than those in phase III ($P_1=0.021$; $P_2=0.004$), and it was also markedly higher in patients without lymph node metastasis than those with (P=0.008). The expression of STMN1 gene was apparently higher in patients in phase I/II than those in phase IV (P=0.002). There was no significant difference between the rest gene expression and the clinical characteristics of NSCLC patients (P>0.05). Additionally, the diseasefree survival (DFS) was significantly longer in patients receiving gene detections than those without (P=0.021). Conclusions: The selection of chemotherapeutic protocols based singly on patients' clinical characteristics has certain blindness. However, the detection of tumor-susceptible genes can guide the postoperative adjuvant chemotherapy and prolong the DFS of NSCLC patients.


Non-small cell lung cancer;real time polymerase chain reaction;target gene;disease-free survival


  1. Arriagada R, Bergman B, Dunant A, et al (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350, 351-60.
  2. Chen CY, Chang YL, Shih JY, et al (2011). Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer, 74, 132-8.
  3. Cui L, Liu XX, Jiang Y, et al (2014)Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702.
  4. Douillard JY, Rosell R, De Lena M, et al (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol, 7, 719-27.
  5. Fang H, Lin RY, Sun MX, et al (2014). Efficacy and survivalassociated factors with gefitinib combined withcisplatin and gemcitabine for advanced non- small cell lung cancer. Asian Pac J Cancer Prev, 15, 10967-70.
  6. Gan PP, Pasquier E, Kavallaris M (2007). Class III ${\beta}$-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res, 67, 9356-63.
  7. Gao H, Ge RC, Liu HY, et al (2014). Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer. Genet Mol Res, 13, 8997-9004.
  8. Hamada C, Tanaka F, Ohta M, et al (2005). Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol, 23, 4999-5006.
  9. Han Y, Wang XB, Xiao N, et al (2013). mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2987-90.
  10. Jeon TY, Han ME, Lee YW, et al (2010). Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer, 102, 710-8.
  11. Ji ZQ, Huang XE, Wu XY, et al (2014)Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5.
  12. Kato H, Ichinose Y, Ohta M, et al (2004). A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med, 350, 1713-21.
  13. Li Z, Qing Y, Guan W, et al (2014). Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol, 74, 777-86.
  14. Miyoshi T, Kondo K, Toba H, et al (2007). Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res, 27, 2641-8.
  15. Nie W, Xu MD, Gan L, et al (2015). Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer. Lab Invest, 95, 56-64.
  16. Pentheroudakis G, Batistatou A, Kalogeras KT, et al (2011). Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat, 127, 179-93.
  17. Pignon JP, Tribodet H, Scagliotti GV, et al (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9.
  18. Rana S, Maples PB, Senzer N, et al (2008). Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther, 8, 1461-70.
  19. Seyhan EC, Altin S, Cetinkaya E, et al (2011). Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg, 17, 110-7.
  20. Strauss GM, Herndon JE, Maddaus MA, et al (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol, 26, 5043-51.
  21. Su C, Zhou S, Zhang L, et al (2011). ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol, 28, 1411-7.
  22. Sun N, Deng C, Zhao X, et al (2014). Extraction of total nucleic acid based on silica-coated magnetic particles for RT-qPCR detection of plant RNA virus/viroid. J Virol Methods, 196, 204-11.
  23. Tseden-Ish M, Choi YD, Cho HJ, et al (2012). Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype. Respirol, 17, 127-33.
  24. Winton T, Livingston R, Johnson D, et al (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 352, 2589-97.
  25. Wu GQ, Liu NN, Xue XL, et al (2014). Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy. Asian Pac J Cancer Prev, 15, 4153-8.
  26. Zhao HY, Ma GW, Zou BY, et al (2014). Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. Onco Targets Ther, 7, 1301-10.

Cited by

  1. Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer vol.35, pp.2, 2017,
  2. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways vol.37, pp.2, 2017,